Niraparib oral capsule
Phase 2
Niraparib oral capsule is one of 9 therapeutic programs targeting Ovarian Cancer Recurrent. It is currently in Phase 2.
1
Indications
1
Total Trials
1
Active Trials
8
Competitors
Pipeline
Status by Indication[2][1]
Indication
Competition
Competitive Landscape
8 competitors in Ovarian Cancer Recurrent
#DrugCompanyPhaseTrials
1Taxol
TevaPreclinical
Keytruda
Merck & Co.Preclinical
Gemzar
Johnson & JohnsonPreclinical
Paraplatin
AAvyxa
Preclinical
Avastin
BBio-Thera Solutions
Preclinical
Raludotatug Deruxtecan
Merck & Co.Preclinical
Rescue Medication
Merck & Co.Preclinical
Pegylated Liposomal Doxorubicin
Merck & Co.Preclinical
Niraparib oral capsule
IInstitute of Cancer Research, United Kingdom
Phase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]Open Targets Platform — Drug–disease associations for Niraparib oral capsule. EMBL-EBI & Wellcome Sanger Institute.
- [3]
Details
Drug Info
Quick Facts
- Highest Phase
- Phase 2[1]